Can you take Chikungunya vaccine, live (cvx 317) with Muromonab-cd3?

muromonab-CD3 has a major potential interaction with Arrhythmia.

The use of muromonab-CD3 is contraindicated in patients with uncompensated heart failure. Cardiovascular collapse, cardiac arrest, severe hypotension, shock, left ventricular dysfunction, and arrhythmias have occurred in patients administered muromonab-CD3. Patients with cardiovascular impairments are at increased risk for more serious cardiorespiratory complications (respiratory arrest, failure, distress, and/or cardiovascular collapse, cardiac arrest, angina, or myocardial infarction) from muromonab-CD3-associated Cytokine Release Syndrome.

muromonab-CD3 has a major potential interaction with Cerebral Vascular Disorder.

The use of muromonab-CD3 is contraindicated in patients with or predisposed to seizures. Seizures, cerebral edema, confusion, auditory/visual hallucinations, mental status changes, psychosis, mania, lethargy, stupor, or coma have occurred in patients administered muromonab-CD3. Patient with CNS disorders, cerebrovascular disease, neurological disturbances are at increased risk for neuro/psychiatric events.

muromonab-CD3 has a moderate potential interaction with Fever.

Muromonab-CD3 should not be administered in the presence of a body temperature of 100 degrees F (38.7 degrees C) or greater. Spiking fever (to 107 degrees F) associated with the Cytokine Release Syndrome have occurred. Antipyretics may be administered to reduce body temperature in this setting.

muromonab-CD3 has a major potential interaction with Fluid Retention.

The use of muromonab-CD3 is contraindicated in patients with fluid overload as evidences by chest X-ray or a 3% or more weight gain in the week prior to muromonab-CD3 therapy. Patients with fluid overload are at increased risk for more serious cardiopulmonary complications (respiratory arrest, failure, distress, and/or cardiovascular collapse, cardiac arrest, angina, or myocardial infarction) from muromonab-CD3-associated Cytokine Release Syndrome.

muromonab-CD3 has a major potential interaction with Head Injury.

The use of muromonab-CD3 is contraindicated in patients with or predisposed to seizures. Seizures, cerebral edema, confusion, auditory/visual hallucinations, mental status changes, psychosis, mania, lethargy, stupor, or coma have occurred in patients administered muromonab-CD3. Patient with CNS disorders, cerebrovascular disease, neurological disturbances are at increased risk for neuro/psychiatric events.

muromonab-CD3 has a major potential interaction with Heart Failure.

The use of muromonab-CD3 is contraindicated in patients with uncompensated heart failure. Cardiovascular collapse, cardiac arrest, severe hypotension, shock, left ventricular dysfunction, and arrhythmias have occurred in patients administered muromonab-CD3. Patients with cardiovascular impairments are at increased risk for more serious cardiorespiratory complications (respiratory arrest, failure, distress, and/or cardiovascular collapse, cardiac arrest, angina, or myocardial infarction) from muromonab-CD3-associated Cytokine Release Syndrome.

Chikungunya vaccine, live (cvx 317) has a moderate potential interaction with Immunodeficiency.

The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.

muromonab-CD3 has a major potential interaction with Ischemic Heart Disease.

The use of muromonab-CD3 is contraindicated in patients with uncompensated heart failure. Cardiovascular collapse, cardiac arrest, severe hypotension, shock, left ventricular dysfunction, and arrhythmias have occurred in patients administered muromonab-CD3. Patients with cardiovascular impairments are at increased risk for more serious cardiorespiratory complications (respiratory arrest, failure, distress, and/or cardiovascular collapse, cardiac arrest, angina, or myocardial infarction) from muromonab-CD3-associated Cytokine Release Syndrome.

muromonab-CD3 has a major potential interaction with Seizures.

The use of muromonab-CD3 is contraindicated in patients with or predisposed to seizures. Seizures, cerebral edema, confusion, auditory/visual hallucinations, mental status changes, psychosis, mania, lethargy, stupor, or coma have occurred in patients administered muromonab-CD3. Patient with CNS disorders, cerebrovascular disease, neurological disturbances are at increased risk for neuro/psychiatric events.